|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Paxlovid
gptkb:tenofovir
|
|
gptkbp:activities
|
protease inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:1996
gptkb:United_States
|
|
gptkbp:brand
|
Norvir
|
|
gptkbp:can_be_used_with
|
gptkb:atazanavir
darunavir
lopinavir
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:clinical_trial
|
gptkb:drug
ongoing
pre-exposure prophylaxis (Pr EP)
< 5% (oral)
|
|
gptkbp:contraindication
|
hypersensitivity
severe liver disease
|
|
gptkbp:discovered_by
|
gptkb:Abb_Vie
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:formulation
|
gptkb:tablet
combination therapy
oral solution
soft gel capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ritonavir
|
|
gptkbp:indication
|
HIV-1 infection
HIV-1 related conditions
|
|
gptkbp:ingredients
|
C37 H48 N6 O5 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
gptkb:2021
|
|
gptkbp:is_atype_of
|
J05 A E02
|
|
gptkbp:is_effective_against
|
reduces viral load
increases C D4 count
|
|
gptkbp:is_used_for
|
HIV treatment
|
|
gptkbp:lifespan
|
3-5 hours
|
|
gptkbp:marketed_as
|
Norvir
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:previous_name
|
gptkb:battle
|
|
gptkbp:safety_features
|
not recommended for children under 2 years
|
|
gptkbp:side_effect
|
gptkb:lipodystrophy
fatigue
headache
nausea
diarrhea
insulin resistance
hyperlipidemia
hepatotoxicity
QT prolongation
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of
|
155213-67-5
|